Business Description
Assembly Biosciences Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
V7B1.Germany
•
ASMB.USA
Description
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 22.95 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -6.16 | |||||
| Beneish M-Score | 2.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39.3 | |||||
| 3-Year EBITDA Growth Rate | 19.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9 | |||||
| 3-Year FCF Growth Rate | 8 | |||||
| 3-Year Book Growth Rate | -24.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.64 | |||||
| 9-Day RSI | 38.12 | |||||
| 14-Day RSI | 38.57 | |||||
| 6-1 Month Momentum % | -5.26 | |||||
| 12-1 Month Momentum % | -40.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.31 | |||||
| Quick Ratio | 8.31 | |||||
| Cash Ratio | 7.8 | |||||
| Days Sales Outstanding | 28.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1404.88 | |||||
| Net Margin % | -2024.5 | |||||
| ROE % | -70.64 | |||||
| ROA % | -62.78 | |||||
| ROIC % | -181.5 | |||||
| ROC (Joel Greenblatt) % | -1212.01 | |||||
| ROCE % | -46.85 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.33 | |||||
| PB Ratio | 0.66 | |||||
| Price-to-Tangible-Book | 0.66 | |||||
| EV-to-EBIT | 0.35 | |||||
| EV-to-EBITDA | 0.35 | |||||
| EV-to-Revenue | -4.7 | |||||
| EV-to-FCF | 0.37 | |||||
| Price-to-Net-Current-Asset-Value | 0.78 | |||||
| Price-to-Net-Cash | 0.84 | |||||
| Earnings Yield (Greenblatt) % | 296.66 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ASMB
Peter Lynch Chart
Performance
Dividend
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.254 | ||
| EPS (TTM) ($) | -2.77 | ||
| Beta | 0.51 | ||
| Volatility % | 56.55 | ||
| 14-Day RSI | 38.57 | ||
| 14-Day ATR ($) | 0.103862 | ||
| 20-Day SMA ($) | 1.83 | ||
| 12-1 Month Momentum % | -40.54 | ||
| 52-Week Range ($) | 1.3199 - 3.385 | ||
| Shares Outstanding (Mil) | 48.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Assembly Biosciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Assembly Biosciences Inc Analysis
Share your researchHeadlines
See More
No news.